Insights - Merrimack Pharmaceuticals’ (MACK) MM-121 failed to meet its primary endpoint in a study for the treatment of women with ER/PR+, HER2 negative metastatic breast cancer … Continue Reading
Read NowInsights - Orexigen Therapeutics’ (OREX) obesity drug Contrave did not increase the risk of cardiovascular events (heart attack, etc.) past a specified threshold in an interim look … Continue Reading
Premium: Read NowInsights - ImmunoCellular Therapeutics’ (IMUC) stock is up 24% on Monday following ROTH Capital’s price target raise, to $9 (from $6), the firm adding the stock to its … Continue Reading
Premium: Read NowInsights - Threshold Pharmaceuticals (THLD) on Friday announced early data from the Phase 1 portion of an investigator-sponsored Phase 1/2 trial of its investigational hypoxia-targeted drug TH-302 … Continue Reading
Read NowInsights - Sarilumab, a new Rheumatoid Arthritis (RA) drug from Sanofi (SNY) and Regeneron (REGN), showed positive results in its first Phase 3 clinical trial. If approved, … Continue Reading
Read NowInsights - Forest Laboratories Inc. (FRX) and Gedeon Richter Plc. announced that the U.S. Federal Drug Administration (FDA) issued a complete response letter regarding the New Drug … Continue Reading
Read NowInsights - Amgen’s (AMGN) PCSK9 inhibitor evolucumab (AMG145), when added to standard treatments, helped 86% of patients get their LDL cholesterol levels to a target of 100 … Continue Reading
Read Now
